.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Cerilliant
US Army
Queensland Health
Deloitte
Julphar
Moodys
Colorcon
Teva
Boehringer Ingelheim

Generated: December 17, 2017

DrugPatentWatch Database Preview

VIVLODEX Drug Profile

« Back to Dashboard

Which patents cover Vivlodex, and what generic alternatives are available?

Vivlodex is a drug marketed by Iroko Pharms Llc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in thirteen countries.

The generic ingredient in VIVLODEX is meloxicam. There are twenty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Iroko Pharms LlcVIVLODEXmeloxicamCAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Iroko Pharms LlcVIVLODEXmeloxicamCAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Iroko Pharms LlcVIVLODEXmeloxicamCAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
Iroko Pharms LlcVIVLODEXmeloxicamCAPSULE;ORAL207233-001Oct 22, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Iroko Pharms LlcVIVLODEXmeloxicamCAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Iroko Pharms LlcVIVLODEXmeloxicamCAPSULE;ORAL207233-002Oct 22, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for VIVLODEX

Drugname Dosage Strength RLD Submissiondate
meloxicamCapsules5 mg and 10 mgVivlodex1/9/2017

Non-Orange Book Patents for Tradename: VIVLODEX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,808,468Formulation of meloxicam► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: VIVLODEX

Country Document Number Estimated Expiration
Eurasian Patent Organization201692392► Subscribe
Australia2015274838► Subscribe
Singapore11201610179Q► Subscribe
Canada2951383► Subscribe
Philippines12016502336► Subscribe
Japan2017517551► Subscribe
Mexico2016016212► Subscribe
Uruguay36172► Subscribe
China107073010► Subscribe
Israel248699► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Teva
Cerilliant
Johnson and Johnson
Federal Trade Commission
Dow
Chubb
Farmers Insurance
QuintilesIMS
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot